๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
NCT05593458Locally Advanced Gastric Carcinoma
Zhejiang University
Phase 3
190
Hangzhou
2023-03-01
Recruiting
Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
NCT06164769Tumor of Pancreas, Surgical Blood Loss
Zhejiang University
Not applicable
30
Hangzhou
2023-03-01
Not yet open
Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
NCT05602974Hepatocellular Carcinoma, Narrow Margin, Adjuvant Stereotactic Body Radiotherapy, Hepatectomy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2023-03-01
Recruiting
Association of Gestational Cardiovascular Health With Pregnancy Outcomes
NCT05776082Pregnant Women
Women's Hospital School Of Medicine Zhejiang University
Observational
5,000
Hangzhou, Taizhou
2023-03-01
Recruiting
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
NCT05595603Giant Cell Tumor of Bone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
153
Hangzhou
2023-03
Not yet open
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
NCT05699746Colorectal Cancer
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Active, closed
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06198413Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 1
12
Hefei, Hangzhou, Shanghai
2023-02-27
Recruiting
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
NCT05731726pMMR, MSS, MSI-L, Locally Advanced Rectal Carcinoma
Zhejiang University
Phase 2
50
Hangzhou
2023-02-22
Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT05800977Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
By invitation
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531Spinal Muscular Atrophy Type I
Guangzhou Jiayin Biotech Ltd
Phase 1/2
12
Shanghai, Hangzhou
2023-02-16
Active, closed
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
NCT05557838Hepatocellular Carcinoma
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Active, closed
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
NCT05673785Lymphoma
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Recruiting
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
NCT05913960Major Depressive Disorder, Major Depressive Disorder, Recurrent
First Affiliated Hospital of Zhejiang University
Not applicable
90
Hangzhou
2023-02-09
Recruiting
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NCT05565807Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1/2
84
Beijing, Guangzhou, Hangzhou
2023-02-09
Recruiting
Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children
NCT06048445Liver Transplant; Complications
Zhejiang University
Observational
108
Hangzhou
2023-02-07
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Recruiting
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
NCT07014410Breast Cancer
Zhejiang Cancer Hospital
Phase 2
63
Hangzhou
2023-02-01
Active, closed
Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
NCT05742204Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,700
Hangzhou
2023-02-01
Recruiting
Radiomics-based Malnutrition for Cervical Cancer.
NCT05709769Cervical Cancer, Malnutrition
Zhejiang Provincial People's Hospital
Observational
150
Hangzhou
2023-01-31
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an, Zhejiang
2023-01-12
Recruiting
Clinical Study of OR for Second-line Treatment of Refractory MZL
NCT06134284OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng
Phase 4
39
Hangzhou, Ningbo
2023-01-02
Recruiting
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NCT04960839Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
323
Jiangxi, Shanghai, Hangzhou
2023-01-01
Recruiting
Idiopathic Generalized Epilepsy Syndromes
NCT06388174Epilepsy, Epilepsy, Idiopathic Generalized
Shen Chun-Hong
Observational
200
Hangzhou
2023-01-01
Recruiting
The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression
NCT05607654Treatment-resistant Depression
First Affiliated Hospital of Zhejiang University
Not applicable
60
Hangzhou
2023-01-01
Recruiting
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
NCT05503875Immunoclassification, Psoriasis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2023-01-01
Not yet open
Prediction of Development and Rupture Risk for Intracranial Unruptured Aneurysms
NCT05576727Intracranial Aneurysm
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2023-01-01
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Active, closed
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752Non Small Cell Lung Cancer, Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Fuzhou, Changsha, Changchun, Hangzhou, Taizhou
2022-12-20
Recruiting
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920Hepatocellular Carcinoma
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
Effect of PRP vs Corticosteroid in Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair
NCT05603468Tendinopathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
387
Hangzhou
2022-12-15
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 3
324
รœrรผmqi, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-12-13
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Genmab
Phase 1/2
884
Beijing, Chongqing, Changsha, Nanchang, Changchun, Chengdu, Shanghai, Hangzhou
2022-12-07
Not yet open
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
NCT05633199Cytoreductive Surgery
Women's Hospital School Of Medicine Zhejiang University
Not applicable
140
Hangzhou
2022-12-01
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT05659251Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2022-12-01
Recruiting
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
NCT05659628Diffuse Large B-cell Lymphoma
Ningbo No. 1 Hospital
Phase 1
24
Hangzhou, Ningbo
2022-12
Recruiting
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
NCT05620017Advanced Solid Tumors
Bio-Thera Solutions
Phase 1
182
Chongqing, Hangzhou
2022-11-30
Active, closed
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
Pfizer
Phase 1
148
Hangzhou, Wenzhou
2022-11-30
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao
2022-11-21
Active, closed
Primary Cervical Cancer Screening by Self-sampling HPV Test
NCT05613283Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
Peking University People's Hospital
Observational
17,875
Beijing, Zhengzhou, Changsha, Chengdu, Hangzhou
2022-11-19
Recruiting
Arthroscopic Anterior Cruciate Ligament Repair Versus Reconstruction for Acute Anterior Cruciate Ligament Injury
NCT05584020Anterior Cruciate Ligament Injuries
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2022-11-18
Active, closed
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NCT05374603Lung Cancer
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Recruiting
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC๏ผˆneoSCORE โ…ก๏ผ‰
NCT05429463Squamous Cell Non-small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
250
Hangzhou
2022-11-11
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Active, closed
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
NCT05451290Advanced Biliary Tract Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou
2022-11-01
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
864
Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2022-10-13
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Active, closed
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
NCT05379946Solid Tumor
InventisBio Co., Ltd
Phase 1/2
92
Hangzhou
2022-10-12
Active, closed
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
NCT06166836Solid Tumor
InxMed (Shanghai) Co., Ltd.
Phase 1/2
140
Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou
2022-10-12
Active, closed
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT07226752Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Recruiting
Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy
NCT07124572Thyroid Associated Ophthalmopathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2022-10-01
Recruiting
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
NCT05543330Malignant Pleural Effusions, NSCLC Stage IV
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2
116
Hangzhou
2022-09-30
Active, closed
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
NCT05462353Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Gannex Pharma Co., Ltd.
Phase 2
183
Hangzhou
2022-09-30
Recruiting
Micro-expressions in Patients With Prolonged Disorders of Consciousness
NCT06088628Consciousness Disorders
First Affiliated Hospital of Zhejiang University
Observational
200
Hangzhou
2022-09-27
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
Chaoyang, Chengdu, Hangzhou, Jinhua, Nanjing, Wuhan
2022-09-19
Recruiting
Specific Dietary Pattern for Crohn's Disease Patients Following Surgery
NCT05502965Crohn Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
35
Hangzhou
2022-09-17
Recruiting
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
NCT05652192Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
37
Hangzhou
2022-09-15
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Recruiting
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
NCT05482568Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
324
Shanghai, Hangzhou
2022-09-15
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505MRD
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
NCT05536089Cancer Colorectal
Singlera Genomics Inc.
Observational
2,000
Hangzhou
2022-09-05
Recruiting
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
NCT05446467Head and Neck Squamous Cell Carcinoma
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Active, closed
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
NCT05460767Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
504
Hangzhou
2022-08-31
Recruiting
Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
NCT05512286Breast Cancer
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
NCT05477849Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hangzhou
2022-08-23
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Recruiting
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809699Hematologic Diseases
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809712Hematologic Disease
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
NCT05514275Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Recruiting
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
NCT05992597Rituximab, Lenalidomide, Zebutinib ๏ผŒMantle Cell Lymphoma
Zhejiang Cancer Hospital
Phase 2
48
Hangzhou
2022-08-01
Recruiting
Eluvia DES for the Patients with Femoropopliteal Artery Lesions.
NCT05522218Vascular Diseases, Stent Complication
First Affiliated Hospital of Zhejiang University
Observational
400
Hangzhou
2022-08-01
Active, closed
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT05457257Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC
Phase 1/2
225
Dalian, Guangzhou, Hangzhou, Wuhan
2022-07-29
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Recruiting
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
NCT05501353Colorectal Cancer Metastatic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
NCT05246514HER2-mutant Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
A Study for the Adjuvant Treatment of Breast Cancer
NCT05420467Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,413
Hangzhou
2022-07-10
Recruiting
A Study for the Neoadjuvant Treatment of Breast Cancer
NCT05420454Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
1,576
Hangzhou
2022-07-10
Recruiting
Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia
NCT05431010Sarcopenia
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
120
Hangzhou
2022-07-02
Recruiting
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
NCT05433935Intraductal Papillary Mucinous Neoplasm
Zhejiang University
Observational
5,000
Hangzhou
2022-07-01
Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05722405Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2022-07-01
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Active, closed
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
NCT06267742Sepsis
Beckman Coulter, Inc.
Observational
2,200
Beijing, Chengdu, Hangzhou
2022-06-23
Active, closed
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
NCT05235516Locally Advanced Cervical Carcinoma
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Active, closed
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
NCT05363800Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
74
Zhengzhou, Shengyang, Hangzhou
2022-06-17
Rows per page Showing 1401–1500 of 1812
Previous 13 14 15 16 17 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=15

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.